Remyelination

Last updated

Remyelination is the process of propagating oligodendrocyte precursor cells to form oligodendrocytes to create new myelin sheaths on demyelinated axons in the CNS. This is a process naturally regulated in the body and tends to be very efficient in a healthy CNS. [1] The process creates a thinner myelin sheath than normal, but it helps to protect the axon from further damage, from overall degeneration, and proves to increase conductance once again. The processes underlying remyelination are under investigation in the hope of finding treatments for demyelinating diseases, such as multiple sclerosis.

Contents

As of 2022 the status of possible remyelination acceleration is of trials only, [2] with side effects of possible drugs one limiting issue. [3]

Function

Remyelination is activated and regulated by a variety of factors surrounding lesion sites that control the migration and differentiation of Oligodendrocyte Precursor Cells. Remyelination looks different from developmental myelination in the structure of the myelin formed. Reasons for this are unclear, but proper function of the axon is restored regardless. Perhaps of most interest are the inhibition and promotion factors of this physiological process. One way this process can be traced is by following different protein activation sequences which have shown just how quickly remyelination begins after injury (within a few of days). [4]

Characteristics of remyelinated axons

The most notable evidence that remyelination has taken place on an axon is its thin myelin sheath created by an oligodendrocyte, though the reason why the new myelin sheath is thinner remains unclear. This can be quantified in the g-ratio, the ratio between the diameter of the axon itself to the outer diameter of the myelinated fiber. Remyelinated axons tend to have values closer to 1, indicating a thinner myelin sheath than those myelinated naturally. The g-ratio differences are less apparent on smaller axons. [1]

Myelin Sheaths in the CNS. Neuron with oligodendrocyte and myelin sheath.svg
Myelin Sheaths in the CNS.

The thinner myelin not only restores protection of the axon from degradation, [5] but also restores a faster conduction velocity. The conduction velocity, however, is not as strong as naturally myelinated axons and the Nodes of Ranvier are inclined to be wider which results in less coverage in the axon by myelin than what is natural. [6]

OPC involvement

Oligodendrocyte Precursor Cells, or OPC's, are the main cells responsible for the remyelination of demyelinated axons. There are two physiological changes that must occur to OPC's for remyelination to occur. [1] Once a signal is sent that remyelination is needed, OPC's will first migrate to the damaged axon. This process may be signaled or enhanced by microglia or astrocytes at the injured axon site that stimulate migratory OPC pathways [1] From there the cells must differentiate from being progenitors to being pre-oligodendrocytes, then premyelinating oligodendrocytes, and finally mature oligodendrocytes. [6] These oligodendrocytes can then wrap damaged axons with new myelin sheaths. This process of differentiation through several phases has many involved and direct pathways and factors necessary for the completion of this process. It is easy to completely stop remyelination with the failure of a number of pathways.

Propagation factors

One of the difficulties of studying remyelination is the variety of factors that play a role in differentiating oligodendrocyte progenitors. While some factors promote and others inhibit, still some factors that are known to be involved are yet not understood enough to know whether it promotes, inhibits, or does both. Many factors are poorly understood and subject to much change as research is done.

Cytokines and chemokines

Cytokines mediate inflammatory responses that promote pathogen and debris clearance so that further tissue damage is avoided. [1] [6] [7] Too much can mean cell death but failure to propagate cytokines at all in remyelination results in a lack of debris clearance at a damaged axon site; this buildup of myelin and oligodendrocyte debris has been shown to inhibit the differentiation of Oligodendrocyte Precursor Cells. [1] Specifically, cytokines promote TNFR2 and eventually TNF-alpha which plays a key role in OPC differentiation. [7]

It has also been shown that chemokines are involved in guiding immune cells to sites of axon lesions to facilitate inflammation and debris clearance as well as possibly guiding OPCs migration to lesion sites. So then, chemokines are directly involved with both migration and differentiation of OPCs. [7] The specific chemokines involved with each of these two processes is known: CXCL12 is related to migration and differentiation is increased with an increase in CXCR7 and a decrease in CXCR4. [7] In certain demyelinating diseases CXCL12 has been shown to be decreased, possibly playing a role in demyelination failure. Still much is to be researched in this field, as certain chemokines like CXCR2 plays a role in inflammation and repair but in an unknown manner over much controversy. [7]

Signaling pathways

LINGO1, a cell receptor, has been proposed to be involved in the regulation of remyelination. It is thought to inhibit not only axon regeneration but also regulate oligodendrocyte maturation by inhibiting OPC differentiation. Animal studies suggest that when a LINGO1 is inhibited, [8] OPC differentiation and thus remyelination can be promoted at demyelinated sites. LINGO1 gene expression is also known to activate RhoA which may also play a part in inhibition. [1] [6] [7] Myelin debris build up might be responsible for the promotion of the LINGO1 signalling and overall inhibition. [6] [9] [10]

The Notch-1 receptor pathway is another pathway that inhibits the differentiation of OPCs. [6] When the ligands Jagged1 and Delta, produced by axons, neurons, and astrocytes, are stimulated and bind to the membrane, oligodendrocyte maturation is inhibited. This pathway may also be facilitating migration despite its differentiation inhibition. [7] In some experiments, altering the pathway so that differentiation is increased caused a decrease in the proliferation of OPCs. [11] There may be other ligands that have either promoting or inhibiting effects when attached to the Notch-1 receptor. [1] [11]

The Wnt-β-Catelin pathway has been shown to also inhibit remyelination when it is dysregulated in the body. Demyelinating diseases have been shown to cause this dysregulation. Possible genes involved inside this pathway are TCF4 and OLIG2 which are both expressed in high amounts in areas where remyelination has failed from demyelinating diseases. [6] [12]

Transcription factors

Gene expression may be the most important factor in understanding remyelination and can hold the key to understanding how to treat demyelinating diseases. OLIG1 has been shown to be critical in developmental myelination and may also be important in remyelination. [7] OLIG2 and TRF4 have also been shown to be important especially in the Wnt-β-Catenin Pathway, most likely in inhibiting remyelination. NKX2-2 is a gene coding for a protein that may increase the number of OPCs in low amounts, possibly working with OLIG2 in some way to differentiate OPCs to mature oligodendrocytes. [7] As more genes involved in remyelination are found and cross linked more will be understood about promotion and inhibition.

Androgen receptor (AR) and testosterone

In a mouse model, it has been shown that testosterone, acting through the androgen receptor (AR), is important in remyelination by oligodendrocytes. [13] [14] Those same authors note that the AR evolved from a duplicated gene coincidentally with the development of myelin in jawed vertebrates.

Other factors

It is known that as age increases there's a decrease in the efficiency (both the speed and magnitude) of remyelination at demyelinated axons. This is probably linked with down regulation of certain expressed genes with increased age. The research of this is particularly important with the elderly whose myelin and axons are more prone to be degenerated in the CNS. [1] [15] [16]

Class 3 semaphorins (SEMA3s), originally identified as axon guidance molecules, play a role in remyelination. For instance, SEMA3s modulate the recruitment of oligodendrocyte precursor cells and their differentiation into oligodendrocytes. In addition, SEMA3a is known to repel Schwann cells. [17]

Growth Factors are active polypeptides that control differentiation and biological growth in responsive cells. They have been shown to have a prominent role. Due to the wide variety of these factors it is difficult to study specifically but understanding can be big in treating demyelinating diseases. Some of the factors being researched are EGF (which is known to enhance myelination), IGF-1, PDGF, and FGF [7]

Toll-Like receptors are also involved in remyelination, most likely inhibiting remyelination and OPC differentiation. There are a variety of types of these receptors, but a majority of them tend to increase, especially in the chronic stages of demyelinating diseases, suggesting that they may be involved with remyelination failure. [6] [7]

MicroRNA is not well understood but may play a minor or major role in remyelination. MicroRNA may have a role in reduction of CD47 which promotes phagocytosis of myelin. [7] Certain microRNAs have been shown to promote OPC differentiation by their involvement and maintenance of genes that keep OPCs undifferentiated. [18]

Disease treatment

Understanding completely the inhibiting and promoting factors of OPCs seems to be the key in battling demyelinating diseases such as multiple sclerosis that cause remyelination to fail. [4] Not only are the inhibition factors being looked at as ways to stop remyelination failure, but promotion factors are being looked at to facilitate remyelination in the face of inhibited processes. Stem cell research is also ongoing in seeing how to differentiate neural stem cells into mature oligodendrocytes that will activate at demyelinated sites. [7] Looking at the known factors of developmental myelination may also translate well into remyelination promotion. [7]

Multiple sclerosis

Multiple sclerosis, or MS, is the most prominent of the demyelinating diseases, affecting at least 30 in 100000 people worldwide on average. The ratio is much higher than that in certain areas of the world. While the early stages of multiple sclerosis are less discernible, the chronic stages can greatly reduce an individual's quality of life by limiting motor function. The demyelinating disease attacks the myelin of axons in the central nervous system through autoimmune defects. While remyelination is very efficient in the early stages of multiple sclerosis, it causes remyelination to fail in the more chronic stages. [1] As axons are left bare, without myelin, their conduction velocity goes down due to a lack in increased potential between the Nodes of Ranvier. Not only does conduction go down, but a naked axon is also much more likely to degrade completely, resulting in complete loss of function for certain motor functions. The loss of axons because of lack of protection is what makes MS so debilitating. Degradation is considered to be worse than the effects of demyelination. [5] Once an axon is degenerated, it cannot regenerate like myelin, thus making research to promote remyelination that much more important. MS is more severe in some people than others, most likely from their family genetics and the way that genes are expressed within them. [6] The overall cause for multiple sclerosis itself is completely unknown. Altering important pathways in OPC differentiation such as Notch-1, Wnt, and LINGO1 may prove to be a possible treatment for this disease. [1] [7] [11] Using antibodies to halt or promote certain parts of these pathways could be possible therapies to help increase OPC differentiation. As pathways are better understood, different parts of the pathways can be singled out as possible therapeutic areas to promote remyelination.[ citation needed ]

The results of CCMR-One, a clinical trial of the effects of bexarotene on patients with multiple sclerosis operated by the University of Cambridge, [19] have shown that the drug can cause remyelination, but will not lead to the drug being used as a therapy, due to its risk profile. [20]

Clemastine, an antihistamine drug, has been studied for its potential to possibly promote remyelination and myelin repair in conditions like multiple sclerosis (MS). [21] [22] Early phase II clinical trials showed promise for promoting remyelination in patients with MS, with clemastine improving nerve conduction velocity in the optic nerve. [23] [24] However, a clinical trial (TRAP-MS) was halted in early 2024 after researchers found the disability progression was occurring at a significantly faster rate than anticipated in three participants with MS receiving clemastine. [25] [26] [27]

Future research

Still much is not understood concerning remyelination. New pathways are being discovered constantly in the areas of gene regulation, antibody use as antagonists, and promotion of stem cells to differentiate. There are many regulation factors, such as Lingo-1, Olig-1, Id2, Id4, Hes5, and Sox6, that are not very well understood in their role that may hold the key to developing new treatments for demyelinating diseases. [1] [18]

One of the biggest difficulties of studying demyelinating diseases and thus remyelination is that it takes place in the central nervous system. Studying remyelination most thoroughly would involve unethical and invasive experiments and observation on the human brain and spinal cord. [1] [7] Because of this, scientists are limited to two other methods;

Related Research Articles

<span class="mw-page-title-main">Myelin</span> Fatty substance that surrounds nerve cell axons to insulate them and increase transmission speed

Myelin is a lipid-rich material that surrounds nerve cell axons to insulate them and increase the rate at which electrical impulses pass along the axon. The myelinated axon can be likened to an electrical wire with insulating material (myelin) around it. However, unlike the plastic covering on an electrical wire, myelin does not form a single long sheath over the entire length of the axon. Rather, myelin ensheaths the axon segmentally: in general, each axon is encased in multiple long sheaths with short gaps between, called nodes of Ranvier. At the nodes of Ranvier, which are approximately one thousandth of a mm in length, the axon's membrane is bare of myelin.

<span class="mw-page-title-main">Schwann cell</span> Glial cell type

Schwann cells or neurolemmocytes are the principal glia of the peripheral nervous system (PNS). Glial cells function to support neurons and in the PNS, also include satellite cells, olfactory ensheathing cells, enteric glia and glia that reside at sensory nerve endings, such as the Pacinian corpuscle. The two types of Schwann cells are myelinating and nonmyelinating. Myelinating Schwann cells wrap around axons of motor and sensory neurons to form the myelin sheath. The Schwann cell promoter is present in the downstream region of the human dystrophin gene that gives shortened transcript that are again synthesized in a tissue-specific manner.

<span class="mw-page-title-main">Oligodendrocyte</span> Neural cell type

Oligodendrocytes, also known as oligodendroglia, are a type of neuroglia whose main functions are to provide support and insulation to axons within the central nervous system (CNS) of jawed vertebrates. Their function is similar to that of Schwann cells, which perform the same task in the peripheral nervous system (PNS). Oligodendrocytes accomplish this by forming the myelin sheath around axons. Unlike Schwann cells, a single oligodendrocyte can extend its processes to cover around 50 axons, with each axon being wrapped in approximately 1 μm of myelin sheath. Furthermore, an oligodendrocyte can provide myelin segments for multiple adjacent axons.

<span class="mw-page-title-main">Demyelinating disease</span> Any neurological disease in which the myelin sheath of neurons is damaged

A demyelinating disease refers to any disease affecting the nervous system where the myelin sheath surrounding neurons is damaged. This damage disrupts the transmission of signals through the affected nerves, resulting in a decrease in their conduction ability. Consequently, this reduction in conduction can lead to deficiencies in sensation, movement, cognition, or other functions depending on the nerves affected.

Oligodendrocyte progenitor cells (OPCs), also known as oligodendrocyte precursor cells, NG2-glia, O2A cells, or polydendrocytes, are a subtype of glia in the central nervous system named for their essential role as precursors to oligodendrocytes. They are typically identified in the human by co-expression of PDGFRA and CSPG4.

<span class="mw-page-title-main">Myelin oligodendrocyte glycoprotein</span>

Myelin oligodendrocyte glycoprotein (MOG) is a glycoprotein believed to be important in the myelination of nerves in the central nervous system (CNS). In humans this protein is encoded by the MOG gene. It is speculated to serve as a necessary "adhesion molecule" to provide structural integrity to the myelin sheath and is known to develop late on the oligodendrocyte.

Experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE), is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). It is mostly used with rodents and is widely studied as an animal model of the human CNS demyelinating diseases, including multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). EAE is also the prototype for T-cell-mediated autoimmune disease in general.

<span class="mw-page-title-main">Pathophysiology of multiple sclerosis</span>

Multiple sclerosis is an inflammatory demyelinating disease of the CNS in which activated immune cells invade the central nervous system and cause inflammation, neurodegeneration, and tissue damage. The underlying cause is currently unknown. Current research in neuropathology, neuroimmunology, neurobiology, and neuroimaging, together with clinical neurology, provide support for the notion that MS is not a single disease but rather a spectrum.

<span class="mw-page-title-main">Lesional demyelinations of the central nervous system</span>

Multiple sclerosis and other demyelinating diseases of the central nervous system (CNS) produce lesions and glial scars or scleroses. They present different shapes and histological findings according to the underlying condition that produces them.

Neuroregeneration involves the regrowth or repair of nervous tissues, cells or cell products. Neuroregenerative mechanisms may include generation of new neurons, glia, axons, myelin, or synapses. Neuroregeneration differs between the peripheral nervous system (PNS) and the central nervous system (CNS) by the functional mechanisms involved, especially in the extent and speed of repair. When an axon is damaged, the distal segment undergoes Wallerian degeneration, losing its myelin sheath. The proximal segment can either die by apoptosis or undergo the chromatolytic reaction, which is an attempt at repair. In the CNS, synaptic stripping occurs as glial foot processes invade the dead synapse.

Myelinogenesis is the formation and development of myelin sheaths in the nervous system, typically initiated in late prenatal neurodevelopment and continuing throughout postnatal development. Myelinogenesis continues throughout the lifespan to support learning and memory via neural circuit plasticity as well as remyelination following injury. Successful myelination of axons increases action potential speed by enabling saltatory conduction, which is essential for timely signal conduction between spatially separate brain regions, as well as provides metabolic support to neurons.

<span class="mw-page-title-main">LINGO1</span> Protein-coding gene in the species Homo sapiens

Leucine rich repeat and Immunoglobin-like domain-containing protein 1 also known as LINGO-1 is a protein which is encoded by the LINGO1 gene in humans. It belongs to the family of leucine-rich repeat proteins which are known for playing key roles in the biology of the central nervous system. LINGO-1 is a functional component of the Nogo receptor also known as the reticulon 4 receptor.

<span class="mw-page-title-main">Corinne Goldsmith Dickinson Center for Multiple Sclerosis</span>

The Corinne Goldsmith Dickinson Center for Multiple Sclerosis is a multiple sclerosis research and treatment center in New York City.

Gliogenesis is the generation of non-neuronal glia populations derived from multipotent neural stem cells.

<span class="mw-page-title-main">Myelin regulatory factor</span> Mammalian protein found in Homo sapiens

Myelin regulatory factor, also known as myelin gene regulatory factor (MRF), is a protein that in humans is encoded by the MYRF gene.

<span class="mw-page-title-main">Pathology of multiple sclerosis</span> Pathologic overview

Multiple sclerosis (MS) can be pathologically defined as the presence of distributed glial scars (scleroses) in the central nervous system that must show dissemination in time (DIT) and in space (DIS) to be considered MS lesions.

MOG antibody disease (MOGAD) or MOG antibody-associated encephalomyelitis (MOG-EM) is an inflammatory demyelinating disease of the central nervous system. Serum anti-myelin oligodendrocyte glycoprotein antibodies are present in up to half of patients with an acquired demyelinating syndrome and have been described in association with a range of phenotypic presentations, including acute disseminated encephalomyelitis, optic neuritis, transverse myelitis, and neuromyelitis optica.

Patrizia Casaccia is an Italian neuroscientist who is the Director of the Neuroscience Initiative of the Advanced Science Research Center at the CUNY Graduate Center, as well as a Professor of Neuroscience, Genetics & Genomics, and Neurology at the Icahn School of Medicine at Mount Sinai. Casaccia is a pioneer in the study of myelin. Her research focuses on understanding the neurobiological and neuroimmune mechanisms of multiple sclerosis and to translate findings into treatments. Casaccia co-founded the Center for Glial Biology at Mount Sinai and CUNY and is one of the Directors of the center.

<span class="mw-page-title-main">Véronique Miron</span>

Véronique E. Miron is the John David Eaton Chair in Multiple Sclerosis Research at the Barlo MS Centre and Keenan Research Centre for Biomedical Science, Full Professor at the University of Toronto Department of Immunology, and Honorary Chair at the University of Edinburgh Dementia Research Institute.

A myelinoid or myelin organoid is a three dimensional in vitro cultured model derived from human pluripotent stem cells (hPSCs) that represents various brain regions, the spinal cord or the peripheral nervous system in early fetal human development. Myelinoids have the capacity to recapitulate aspects of brain developmental processes, microenvironments, cell to cell interaction, structural organization and cellular composition. The differentiating aspect dictating whether an organoid is deemed a cerebral organoid/brain organoid or myelinoid is the presence of myelination and compact myelin formation that is a defining feature of myelinoids. Due to the complex nature of the human brain, there is a need for model systems which can closely mimic complicated biological processes. Myelinoids provide a unique in vitro model through which myelin pathology, neurodegenerative diseases, developmental processes and therapeutic screening can be accomplished.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Franklin, Robin J. M.; ffrench-Constant, Charles (November 2008). "Remyelination in the CNS: from biology to therapy". Nature Reviews Neuroscience. 9 (11): 839–855. doi:10.1038/nrn2480. PMID   18931697.
  2. ↑ Brown, J. William L.; Prados, Ferran; Altmann, Daniel R.; Kanber, Baris; Stutters, Jonathan; Cunniffe, Nick G.; Jones, Joanne L.; Georgieva, Zoya G.; Needham, Edward J.; Daruwalla, Cyrus; Wheeler-Kingshott, Claudia Gandini; Connick, Peter; Chandran, Siddharthan; Franklin, Robin; MacManus, David; Samson, Rebecca; Coles, Alasdair; Chard, Declan (October 2022). "Remyelination varies between and within lesions in multiple sclerosis following bexarotene". Annals of Clinical and Translational Neurology. 9 (10): 1626–1642. doi:10.1002/acn3.51662. PMC   9539389 . PMID   36116011.
  3. ↑ Brown, J William L; Cunniffe, Nick G; Prados, Ferran; Kanber, Baris; Jones, Joanne L; Needham, Edward; Georgieva, Zoya; Rog, David; Pearson, Owen R; Overell, James; MacManus, David; Samson, Rebecca S; Stutters, Jonathan; ffrench-Constant, Charles; Gandini Wheeler-Kingshott, Claudia A M; Moran, Carla; Flynn, Paul D; Michell, Andrew W; Franklin, Robin J M; Chandran, Siddharthan; Altmann, Daniel R; Chard, Declan T; Connick, Peter; Coles, Alasdair J (September 2021). "Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study". The Lancet Neurology. 20 (9): 709–720. doi:10.1016/S1474-4422(21)00179-4. PMID   34418398.
  4. 1 2 Lindner, M.; Heine, S.; Haastert, K.; Garde, N.; Fokuhl, J.; Linsmeier, F.; Grothe, C.; Baumgärtner, W.; Stangel, M. (February 2008). "Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination". Neuropathology and Applied Neurobiology. 34 (1): 105–114. doi:10.1111/j.1365-2990.2007.00879.x. PMID   17961136. S2CID   34855686.
  5. 1 2 Irvine, K. A.; Blakemore, W. F. (29 January 2008). "Remyelination protects axons from demyelination-associated axon degeneration". Brain. 131 (6): 1464–1477. doi: 10.1093/brain/awn080 . PMID   18490361.
  6. 1 2 3 4 5 6 7 8 9 Hanafy, Khalid A.; Sloane, Jacob A. (December 2011). "Regulation of remyelination in multiple sclerosis". FEBS Letters. 585 (23): 3821–3828. doi: 10.1016/j.febslet.2011.03.048 . PMID   21443876.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Patel, Jigisha R.; Klein, Robyn S. (December 2011). "Mediators of oligodendrocyte differentiation during remyelination". FEBS Letters. 585 (23): 3730–3737. doi:10.1016/j.febslet.2011.04.037. PMC   3158966 . PMID   21539842.
  8. ↑ Mi, Sha; Miller, Robert H.; Tang, Wei; Lee, Xinhua; Hu, Bing; Wu, Wutain; Zhang, Yiping; Shields, Christopher B.; Zhang, Yongjie; Miklasz, Steven; Shea, Diana; Mason, Jeff; Franklin, Robin J. M.; Ji, Benxiu; Shao, Zhaohui; Chédotal, Alain; Bernard, Frederic; Roulois, Aude; Xu, Janfeng; Jung, Vincent; Pepinsky, Blake (March 2009). "Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells". Annals of Neurology. 65 (3): 304–315. doi: 10.1002/ana.21581 . PMID   19334062. S2CID   24181997.
  9. ↑ Kotter, Mark R.; Li, Wen-Wu; Zhao, Chao; Franklin, Robin J. M. (4 January 2006). "Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation". The Journal of Neuroscience. 26 (1): 328–332. doi:10.1523/JNEUROSCI.2615-05.2006. PMC   6674302 . PMID   16399703.
  10. ↑ Baer, Alexandra S.; Syed, Yasir A.; Kang, Sung Ung; Mitteregger, Dieter; Vig, Raluca; ffrench-Constant, Charles; Franklin, Robin J. M.; Altmann, Friedrich; Lubec, Gert; Kotter, Mark R. (February 2009). "Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling". Brain. 132 (2): 465–481. doi:10.1093/brain/awn334. PMC   2640211 . PMID   19208690.
  11. 1 2 3 Zhang, Yueting; Argaw, Azeb Tadesse; Gurfein, Blake T.; Zameer, Andleeb; Snyder, Brian J.; Ge, Changhui; Lu, Q. Richard; Rowitch, David H.; Raine, Cedric S.; Brosnan, Celia F.; John, Gareth R. (10 November 2009). "Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination". Proceedings of the National Academy of Sciences. 106 (45): 19162–19167. Bibcode:2009PNAS..10619162Z. doi: 10.1073/pnas.0902834106 . PMC   2776461 . PMID   19855010.
  12. ↑ Fancy, Stephen P.J.; Baranzini, Sergio E.; Zhao, Chao; Yuk, Dong-In; Irvine, Karen-Amanda; Kaing, Sovann; Sanai, Nader; Franklin, Robin J.M.; Rowitch, David H. (July 2009). "Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS". Genes & Development. 23 (13): 1571–1585. doi:10.1101/gad.1806309. PMC   2704469 . PMID   19515974.
  13. ↑ Bielecki, Bartosz; Mattern, Claudia; Ghoumari, Abdel M.; Javaid, Sumaira; Smietanka, Kaja; Abi Ghanem, Charly; Mhaouty-Kodja, Sakina; Ghandour, M. Said; Baulieu, Etienne-Emile; Franklin, Robin J. M.; Schumacher, Michael; Traiffort, Elisabeth (20 December 2016). "Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin". Proceedings of the National Academy of Sciences. 113 (51): 14829–14834. Bibcode:2016PNAS..11314829B. doi: 10.1073/pnas.1614826113 . PMC   5187716 . PMID   27930320.
  14. ↑ Hussain, Rashad; Ghoumari, Abdel M.; Bielecki, Bartosz; Steibel, Jérôme; Boehm, Nelly; Liere, Philippe; Macklin, Wendy B.; Kumar, Narender; Habert, René; Mhaouty-Kodja, Sakina; Tronche, François; Sitruk-Ware, Regine; Schumacher, Michael; Ghandour, M. Said (January 2013). "The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination". Brain. 136 (1): 132–146. doi:10.1093/brain/aws284. PMC   4572509 . PMID   23365095.
  15. ↑ Shen, Siming; Sandoval, Juan; Swiss, Victoria A; Li, Jiadong; Dupree, Jeff; Franklin, Robin J M; Casaccia-Bonnefil, Patrizia (September 2008). "Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency". Nature Neuroscience. 11 (9): 1024–1034. doi:10.1038/nn.2172. PMC   2656679 . PMID   19160500.
  16. ↑ de la Fuente, Alerie Guzman; Dittmer, Marie; Heesbeen, Elise J.; de la Vega Gallardo, Nira; White, Jessica A.; Young, Andrew; McColgan, Tiree; Dashwood, Amy; Mayne, Katie; Cabeza-Fernández, Sonia; Falconer, John; Rodriguez-Baena, Francisco Javier; McMurran, Christopher E.; Inayatullah, Mohammed; Rawji, Khalil S.; Franklin, Robin J. M.; Dooley, James; Liston, Adrian; Ingram, Rebecca J.; Tiwari, Vijay K.; Penalva, Rosana; Dombrowski, Yvonne; Fitzgerald, Denise C. (11 March 2024). "Ageing impairs the regenerative capacity of regulatory T cells in mouse central nervous system remyelination". Nature Communications. 15 (1): 1870. Bibcode:2024NatCo..15.1870D. doi:10.1038/s41467-024-45742-w. PMID   38467607.
  17. ↑ Mecollari, V; Nieuwenhuis, B; Verhaagen, J (2014). "A perspective on the role of class III semaphorin signaling in central nervous system trauma". Frontiers in Cellular Neuroscience. 8: 328. doi: 10.3389/fncel.2014.00328 . PMC   4209881 . PMID   25386118.
  18. 1 2 Emery, B. (4 November 2010). "Regulation of Oligodendrocyte Differentiation and Myelination". Science. 330 (6005): 779–782. Bibcode:2010Sci...330..779E. doi:10.1126/science.1190927. PMID   21051629. S2CID   6904322.
  19. ↑ "Trials in Cambridge". Cambridge Neuroimmunology. Retrieved 2020-09-25.
  20. ↑ Sample, Ian (25 September 2020). "MS treatment a step closer after drug shown to repair nerve coating". The Guardian.
  21. ↑ Jiang S, Wang X, Cao T, Kang R, Huang L (2023). "Insights on therapeutic potential of clemastine in neurological disorders". Frontiers in Molecular Neuroscience. 16: 1279985. doi: 10.3389/fnmol.2023.1279985 . PMC   10568021 . PMID   37840769.
  22. ↑ Leigh, Suzanne (12 June 2023). "Can this Medication Reverse MS? Brain Biomarker Shows It Can". UCSF. Retrieved 17 April 2024.
  23. ↑ Riboni-Verri G, Chen BS, McMurran CE, Halliwell GJ, Brown JW, Coles AJ, Cunniffe NG (2024). "Visual outcome measures in clinical trials of remyelinating drugs". BMJ Neurology Open. 6 (1): e000560. doi:10.1136/bmjno-2023-000560. PMC   10882304 . PMID   38389586.
  24. ↑ Moghaddasi M, Nabovvati M, Koushki A, Soltansanjari M, Sardarinia M, Mohebi N, Rabani S (June 2020). "Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis". Clinical Neurology and Neurosurgery. 193: 105741. doi:10.1016/j.clineuro.2020.105741. PMID   32145678.
  25. ↑ Ciccone, Isabella (2 March 2024). "Clemastine Arm of TRAP-MS Trial Halted Following Increased Disability Accumulation in Progressive Multiple Sclerosis". NeurologyLive. Retrieved 17 April 2024.
  26. ↑ Dotinga, Randy (14 March 2024). "Clemastine Tied to Worsening Symptoms in Multidrug MS Trial". Medscape. Retrieved 17 April 2024.
  27. ↑ Maia, Margarida (7 March 2024). "ACTRIMS 2024: An antihistamine may speed MS disease progression". Multiple Sclerosis News Today. Retrieved 17 April 2024.
  28. ↑ Blakemore, WF (1972). "Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice". J. Neurocytol. 1 (4): 413–26. doi:10.1007/bf01102943. PMID   8530973. S2CID   35237115.
  29. ↑ Woodruff, Rachel H.; Franklin, Robin J.M. (February 1999). "Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: A comparative study". Glia. 25 (3): 216–228. doi:10.1002/(sici)1098-1136(19990201)25:3<216::aid-glia2>3.0.co;2-l. PMID   9932868.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.